Shipping to United States We Offer Worldwide Shipping
Login Wishlist

20(R)-Notoginsenoside R2

$360

  • Brand : BIOFRON

  • Catalogue Number : AV-H19085

  • Specification : 98%

  • CAS number : 948046-15-9

  • Formula : C41H70O13

  • Molecular Weight : 770.99

  • PUBCHEM ID : 16757287

  • Volume : 20mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-H19085

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

770.99

Appearance

White crystal

Botanical Source

Panax notoginseng (Burk.)F.H.Chen

Structure Type

Triterpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(CO6)O)O)O)C)O)C)O)C

Synonyms

(3β,6α,12β,20R)-3,12,20-Trihydroxydammar-24-en-6-yl 2-O-β-D-xylopyranosyl-β-D-glucopyranoside/20(S)-Notoginsenoside-R2/β-D-Glucopyranoside, (3β,6α,12β,20R)-3,12,20-trihydroxydammar-24-en-6-yl 2-O-β-D-xylopyranosyl-/R-Notoginsenoside R2/20(R)-NOTOGINSENOSIDE R2

IUPAC Name

(2S,3R,4S,5R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol

Applications

20(R)-Notoginsenoside R2 is an isolated notoginsenoside from Panax notoginseng[1].

Density

1.3±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

485.2±34.3 °C

Boiling Point

878.7±65.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C41H70O13/c1-20(2)10-9-13-41(8,50)21-11-15-39(6)28(21)22(43)16-26-38(5)14-12-27(45)37(3,4)34(38)24(17-40(26,39)7)52-36-33(31(48)30(47)25(18-42)53-36)54-35-32(49)29(46)23(44)19-51-35/h10,21-36,42-50H,9,11-19H2,1-8H3/t21-,22+,23+,24-,25+,26+,27-,28-,29-,30+,31-,32+,33+,34-,35-,36+,38+,39+,40+,41+/m0/s1

InChl Key

FNIRVWPHRMMRQI-RFMRREALSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:948046-15-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

18716453

Abstract

Hip dysplasia (HD) is one of the most important bone and joint diseases in dogs. Making the radiographic diagnosis is sometime possible when the disease has markedly progressed. Chondroitin sulfate (CS) and hyaluronan (HA) are the most important cartilage biomolecules that are elevated in the serum taken from dogs with osteoarthritis. The serum CS and HA can be detected by an ELISA technique, with using monoclonal antibodies against CS epitope 3B3 and WF6 and the HA chain as the primary antibodies. The aim of this study was to compare the levels of serum CS (both epitopes) and HA in non-HD and HD dogs. All 123 dogs were categorized into 2 groups. The non-HD group was composed of 98 healthy dogs, while the HD group was comprised of 25 HD dogs. Blood samples were collected for analyzing the serum CS and HA levels with using the ELISA technique. The results showed that the average serum level of the CS epitope WF6 in the HD group (2,594 ± 3,036.10 ng/ml) was significantly higher than that in the non-HD group (465 ± 208.97 ng/ml) (p < 0.01) while the epitope 3B3 in the HD group (105 ± 100.05 ng/ml) was significantly lower than that in the non-HD group (136 ± 142.03 ng/ml) (p < 0.05). The amount of serum HA in the HD group (134.74 ± 59.71 ng/ml) was lower than that in the non HD group (245.45 ± 97.84 ng/ml) (p < 0.05). The results indicate that the serum CS and HA levels might be used as biomarkers for osteoarthritis in HD dogs.

KEYWORDS

biomarker, chondroitin sulfate, dog, hip dysplasia, osteoarthritis

Title

Evaluation of serum chondroitin sulfate and hyaluronan: biomarkers for osteoarthritis in canine hip dysplasia

Author

Korakot Nganvongpanit,corresponding author1,2 Akanit Itthiarbha,2 Siriwan Ong-Chai,2 Prachya Kongtawelert2

Publish date

2008 Sep 30

PMID

23814475

Abstract

Thirty-one dogs with patellar luxation (grades 2 and 3) were categorized into three groups. Group 1 (G.1; n = 12) had sodium hyaluronate (SHA) intra-articularly injected into the stifle joint that received surgery. Group 2 (G.2; n = 10) received SHA twice: first after surgery and then 1 week later. Group 3 (G.3; n = 9) served as a control, without injection. Blood was collected before injection and then once a week for 4 weeks after injection for evaluation of chondroitin sulfate (CS-WF6) and hyaluronan (HA). The results revealed significantly (p < 0.05) improved clinical scores by the end of week 4 in G.1 and G.2 relative to G.3; however, there was no significant difference between G.1 and G.2. There was a significant decrease (p < 0.05) in serum CS-WF6 levels beginning at week 2 in G.1 and G.2. At weeks 3 and 4, serum HA in G.1 and G.2 differed from that in G.3 (p < 0.05). No significant difference (p > 0.05) was observed in serum biomarkers between G.1 and G.2. In conclusion, intra-articular injection with SHA after joint surgery may improve homeostasis of the joint, retarding the process of OA.

KEYWORDS

biomarker, dog, joint surgery, osteoarthritis, sodium hyaluronate

Title

Effects of one-time and two-time intra-articular injection of hyaluronic acid sodium salt after joint surgery in dogs

Author

Korakot Nganvongpanit,corresponding author1,2 Burin Boonsri,3 Thatdanai Sripratak,3 Patsanan Markmee3

Publish date

2013 Jun 21

PMID

28542897

Abstract

The occurrence of osteoarthritis (OA) in marine mammals is still questionable. Here we investigated the prevalence of OA in marine (dolphin and dugong) and terrestrial mammals (Asian elephant, Asiatic buffalo, camel, cat, cattle, deer, dog, domestic goat, horse, human, hyena, impala, lion, Malayan tapir, Assam macaque, mule, pig, rabbit, red kangaroo, sheep, tiger and waterbuck). Skeletal remains obtained from five institutes were used as subjects; a total of 45 different parts (locations) of bones were observed for OA lesions. The prevalence of OA was reported as number of OA lesions/total number of bones. Our results revealed that the presence of OA in marine species (dolphin and dugong) was 2.44% and 3.33%, respectively. In dolphins, the highest OA occurrence was on the left and right humeral trochlea, with 13.68% and 12.63%, respectively, while the highest number of OA lesions in dugongs was on the lumbar vertebrae (8.79%). No significant difference (P > 0.05) in the prevalence of OA between sexes in dolphins and dugongs was observed, but we found a significant difference (P < 0.05) in 24 bone locations of human bones, which had the highest OA prevalence (48.93%), followed by dogs (3.94%). In conclusion, OA can occur in marine mammals, similar to terrestrial mammals, even though their natural habitat is the ocean.

KEYWORDS

bone, degenerative joint disease, land mammal, marine mammal

Title

Osteoarthritis in two marine mammals and 22 land mammals: learning from skeletal remains

Author

Korakot Nganvongpanit,corresponding author 1 Ratsadakorn Soponteerakul, 1 , † Piyatida Kaewkumpai, 1 , † Veerasak Punyapornwithaya, 2 Kittisak Buddhachat, 3 Raksiri Nomsiri, 4 Patcharaporn Kaewmong, 5 Kongkiat Kittiwatanawong, 5 Rachanchai Chawangwongsanukun, 6 Taweepoke Angkawanish, 7 Chatchote Thitaram, 8 and Pasuk Mahakkanukrauh 9 , 10

Publish date

2017 May 23